RPTX News and Press, Repare Therapeutics Inc. From 09/02/21

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that membe...

Repare Therapeutics (NASDAQ:RPTX): Q2 GAAP EPS of -$0.71 misses by $0.10. Cash and cash equivalents, restricted cash and marketable securities as of June 30, 2021 were $301.0 million. Press Release For further details see: Repare Therapeutics EPS misses by $0.10

Announced dosing of first patient in Phase 1b/2 ATTACC trial of ATR inhibitor RP-3500 and PARP inhibitor combinations in patients with molecularly selected cancers Planning disclosure of initial monotherapy data from the Phase 1/2 TRESR RP-3500 clinical trial early in 4Q21 ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that member...

Repare Therapeutics (RPTX): Q1 GAAP EPS of -$0.58 misses by $0.04.Revenue of $0.17M misses by $0.46M.Cash and cash equivalents, restricted cash and marketable securities of $319.1M.Press Release For further details see: Repare Therapeutics EPS misses by $0.04, misses on revenue

Introduced PKMYT1 as synthetic-lethal target for tumors with CCNE1 amplification or FBXW7 loss and highlighted program progress at RP-6306 Virtual Investor Day Event Announced enrollment of first patient in RP-6306 Phase 1 clinical trial Activated 10 clinical trial sit...

"If you own the turbo-charged growth stocks... you either need to steel yourself for the pain or cut your losses on the next sharp move up, because we're in a new market that’s very different from last year," Jim Cramer said in the latest episode of Mad Money. "What worked in 2020 hasn...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the f...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that membe...

-Company highlights pre-clinical anti-tumor activity of RP-6306, a first-in-class, selective, oral inhibitor of PKMYT1, which is synthetic lethal with CCNE1 amplification and other genomic mutations- - Initiation of Phase 1 clinical trial enrollment for RP-6306 anticipated to ...